Project cooperationUpdated on 17 December 2025
Innovative AI-driven digital tools for Cancer Missions calls
Senior Researcher at Idener
Seville, Spain
About
Idener was started in 2010 by a group of recent PhD graduates with a strong theoretical background in control and systems engineering. Soon, they got fascinated with the early advancements in machine learning, which they incorporated into their research – the seed of the company was already planted. Nowadays, we are a team of engineers, scientists, and software developers exploring AI's potential for solving challenging science and engineering problems. To do so, we use an extended interpretation of AI that fuses machine learning, systems modelling, advanced control, and mathematical optimization. We aim to create new, better, sustainable technologies and business models that ultimately contribute to human development. Our focus is to exploit the potential of AI beyond the software industry, where it still has massive untapped opportunities to create vast amounts of value. Learning from the challenges of our partners, we are developing applications as diverse as green chemical process optimization, improved design of materials, microbial platforms enhancement, child abuse prosecution and environmental regeneration – and yet, we have just scraped the surface of a whole new world of possibilities. It is hard to think of any industry that AI is unlikely to touch in a significant way now or in the near future. So far, we have already developed successful projects across industries, including energy, manufacturing, logistics, chemical processing, biotech, agrifood, and cybersecurity. There, our approach to AI provides real impact as competitive advantage, increased revenues, cost-savings, reduced time-to-market, and business process efficiency.
Topic
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
- DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
GRAD: Your Expert Partner in AI, Digital Twins and Predictive Health
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Sara García Garrido
european project manager at Gradiant
Vigo, Spain
Project cooperation
Nanolive – Cooperation Profile
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
Yann Cotte
CEO at Nanolive
Tolochenaz, Switzerland
Project cooperation
- DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
Jan Ramon
Senior researcher at Inria
Villeneuve d'Ascq, France